Abemaciclib is a potent and selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), and most active against Cyclin D1/CDK4 in enzymatic assays. Abemaciclib prevents retinoblastoma protein (Rb) phosphorylation, blocking cell cycle progression from the G1 to the S-phase of cell division, leading to suppression of tumour growth.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Abemaciclib is the active ingredient of these drugs:
Australia Canada Ecuador Hong Kong Singapore
Austria Brazil Cyprus Estonia Finland
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):